Managing Risks in Health 2.0


By Neil Versel

September 9, 2008 | TORONTO—Interactive media with user-generated content, often generically referred to as Web 2.0, has taken off in health care in the last couple of years. But with all the options and convenience that blogs, wikis, social networking sites, chat rooms, and message boards have opened up for patients and providers alike, the technology known as health 2.0 or medicine 2.0 is not without risk.

“This opens up a multitude of opportunities for patients,” Kevin Clauson, associate professor of pharmacy practice and a specialist in drug information at Nova Southeastern University (Palm Beach Gardens, Fla.), said here Friday at the first Medicine 2.0 Congress, which attracted 180 people from 19 countries for an academic-level discussion on interactive health-IT. He noted that PatientsLikeMe has become a popular forum and virtual support group for those with serious health issues.

Health 2.0 also can open up organizations to embarrassment or possibly even legal liability when it comes to interaction between patients and practitioners. Clauson noted that pharmacists in the U.S. have a “duty to warn” if patients are put in potentially unsafe situations. But it is not clear, Clauson said, if this duty extends to patient-posted content that may indicate that person is taking drugs that may interact with each other.

As more providers move to electronic health records and personal health records that patients can view, the public might be surprised to learn that clinicians have their own form of derogatory slang. Clauson said some popular descriptions he has seen in medical charts include: “CLL” (“chronic low-life”), “LOBNH” (“lights on but nobody home”), and “grave dodger” to describe a chronically ill elderly patient. What happens if patients suddenly start reading such language?

Messages often do get muddled online. E-mails and blogs are wide open to misinterpretation, since it is difficult to communicate tone in typed text. “Poor communication is exacerbated by writing because most people don’t write very well,” Clauson added.

Sometimes, organizations may get hurt by poor judgment that is completely beyond their institutional control. Clauson highlighted a study published in the July issue of the Journal of General Internal Medicine that found that medical students at the University of Florida were less than discrete with some of their Facebook pages. Some belonged to groups called “Physicians Looking for Trophy Wives in Training” or “PIMP: Party of Important Male Physicians.” Others were pictured grabbing the breasts of classmates, visibly drunk, or wearing a lab coat that said “Kevorkian Medical Clinic.”

Clauson recommends that organizations educate their staff about some of the hazards associated with health 2.0 before minor gaffes become major problems. “It is possible to some extent to ameliorate these risks with good judgment and risk management,” he said.

 

 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.